Molecular Imaging and Biology

, Volume 14, Issue 4, pp 517–521 | Cite as

Biodistribution and Radiation Dosimetry of the Serotonin 5-HT6 Ligand [11C]GSK215083 Determined from Human Whole-Body PET

  • Robert A. Comley
  • Cristian Salinas
  • Romina Mizrahi
  • Irina Vitcu
  • Alvina Ng
  • William Hallett
  • Nicholas Keat
  • Alan A. Wilson
  • Eugenii A. Rabiner
  • Marc Laruelle
  • Sylvain Houle
Research Article

Abstract

Purpose

We measured the whole-body distribution of IV-injected [11C]GSK215083, a new 5-HT6 antagonist PET tracer, as a function of time in adult subjects, in order to determine the radiation exposure.

Procedures

After injection with a single bolus of [11C]GSK215083 (range 330–367 MBq; mean 346 MBq), PET emission data were acquired for approximately 120 min in six subjects (three males and three females). Five organs were identified as exhibiting uptake above background. For these, regions of interest were delineated on emission images, and time–activity curves (TAC) generated. Residence times were calculated as the area under the curve of the TAC, normalized to injected activities and standard values of organ volumes. Dosimetry calculations were then performed using the computer program OLINDA/EXM 1.0.

Results

The mean effective dose averaged over both males and females (±standard deviation) was estimated to be 7.7 ± 1.0 μSv/MBq (male 7.0 ± 0.4; female 8.5 ± 0.6). For the effective dose equivalent, the corresponding values are 7.8 ± 1.2 μSv/MBq (male 6.8 ± 0.5; female 8.9 ± 0.1). The organ receiving the highest dose was the lung, with an average equivalent dose of 25.6 ± 6.9 μSv/MBq (male 20.8 ± 5.6; female 30.4 ± 4.4).

Conclusion

The estimated radiation dose for [11C]GSK215083 is consistent with those for other neuroreceptor ligands labeled with carbon-11. The somewhat higher dose estimate for females compared to males may reflect the difference in observed residence times and representative differences in the male and female phantoms used for dosimetry calculations. Based on conventionally accepted dose limits, [11C]GSK215083 may be used for multiple PET scans in the same subject.

Key words

Biodistribution Dosimetry Positron emission tomography [11C]GSK215083 5-HT6 antagonist 

References

  1. 1.
    Ruat M, Traiffort E, Arrang JM, Tardivel-Lacombe J, Diaz J, Leurs R et al (1993) A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. Biochem Biophys Res Commun 193(1):268–276PubMedCrossRefGoogle Scholar
  2. 2.
    Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR (1993) Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 43(3):320–327PubMedGoogle Scholar
  3. 3.
    Yang G, Qiu C, Zhao H, Liu Q, Shao Y (2006) Expression of mRNA for multiple serotonin (5-HT) receptor types/subtypes by the peripheral blood mononuclear cells of rhesus macaques. J Neuroimmunol 178(1–2):24–29PubMedCrossRefGoogle Scholar
  4. 4.
    Stefulj J, Jernej B, Cicin-Sain L, Rinner I, Schauenstein K (2000) mRNA expression of serotonin receptors in cells of the immune tissues of the rat. Brain Behav Immun 14(3):219–224PubMedCrossRefGoogle Scholar
  5. 5.
    Bourson A, Borroni E, Austin RH, Monsma FJ, Sleight AJ (1995) Determination of the role of the 5-ht6 receptor in the rat brain: a study using antisense oligonucleotides. J Pharmacol Exp Ther 274(1):173–180PubMedGoogle Scholar
  6. 6.
    Bourson A, Boess FG, Bös M, Sleight AJ (1998) Involvement of 5-HT6 receptors in nigro-striatal function in rodents. Br J Pharmacol 125(7):1562–1566PubMedCrossRefGoogle Scholar
  7. 7.
    Bentley JC, Bourson A, Boess FG et al (1999) Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04–6790, in rats. Br J Pharmacol 126(7):1537–1542PubMedCrossRefGoogle Scholar
  8. 8.
    Lacroix LP, Dawson LA, Hagan JJ, Heidbreder CA (2004) 5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex. Synapse 51(2):158–164PubMedCrossRefGoogle Scholar
  9. 9.
    Woolley ML, Bentley JC, Sleight AJ, Marsden CA, Fone KC (2001) A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 41(2):210–219PubMedCrossRefGoogle Scholar
  10. 10.
    Rogers DC, Hagan JJ (2001) 5-HT6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacology (Berl) 158(2):114–119CrossRefGoogle Scholar
  11. 11.
    Perez-García G, Meneses A (2005) Oral administration of the 5-HT6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task. Pharmacol Biochem Behav 81(3):673–682PubMedCrossRefGoogle Scholar
  12. 12.
    Woolley ML, Marsden CA, Fone KCF (2004) 5-ht6 receptors. Curr Drug Targets CNS Neurol Disord 3(1):59–79PubMedCrossRefGoogle Scholar
  13. 13.
    Upton N, Chuang TT, Hunter AJ, Virley DJ (2008) 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s disease. Neurotherapeutics 5(3):458–469PubMedCrossRefGoogle Scholar
  14. 14.
    Martarello L, Cunningham VJ, Matthews JC, Rabiner E, Jakobsen S, Gee AD (2005) Radiolabelling and in vivo evaluation of [11C]GSK215083 as potential PET radioligand for the 5-HT6 receptor in the porcine brain. J Cereb Blood Flow Metab 25(S1):S598CrossRefGoogle Scholar
  15. 15.
    Parker CA, Cunningham V, Martarello L et al (2008) Evaluation of the novel 5-HT6 receptor radioligand, [11C]GSK-215083 in human. NeuroImage 41(Supplement 2):T20CrossRefGoogle Scholar
  16. 16.
    Wilson AA, DaSilva JN, Houle S (1994) Facile radiolabelling and purification of 2β-[O-11CH3]-carbomethoxy-3β-aryltropanes: radiotracers for the dopamine transporter. J Label Compd Radiopharm 34:759–765CrossRefGoogle Scholar
  17. 17.
    Wilson AA, Garcia A, Jin L, Houle S (2000) Radiotracer synthesis from [(11)C]-iodomethane: a remarkably simple captive solvent method. Nucl Med Biol 27(6):529–532PubMedCrossRefGoogle Scholar
  18. 18.
    Brambilla M, Secco C, Dominietto M, Matheoud R, Sacchetti G, Inglese E (2005) Performance characteristics obtained for a new 3-dimensional lutetium oxyorthosilicate-based whole-body PET/CT scanner with the National Electrical Manufacturers Association NU 2–2001 standard. J Nucl Med 46(12):2083–2091PubMedGoogle Scholar
  19. 19.
    Defrise M, Kinahan PE, Townsend DW, Michel C, Sibomana M, Newport DF (1997) Exact and approximate rebinning algorithms for 3D-PET data. IEEE Trans Med Imaging 16(2):145–158PubMedCrossRefGoogle Scholar
  20. 20.
    Hamill JJ, Hawman EG (1995) Evaluating a frequency–space SPECT reconstruction algorithm. SPIE vol. 2622. Proc Opt Eng Midwest 95:785–791Google Scholar
  21. 21.
    Watson CC, Newport D, Casey ME, de Kemp RA, Beanlands RS, Schmand M (1997) Evaluation of simulation-base scatter correction for 3D PET cardiac imaging. IEEE Trans Nucl Sci 44(1):90–97CrossRefGoogle Scholar
  22. 22.
    Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46(6):1023–1027PubMedGoogle Scholar
  23. 23.
    van der Aart J, Hallett WA, Rabiner EA, Passchier J, Comley RA (2011) Radiation dose estimates for carbon-11-labelled PET tracers. Nucl Med Biol. 2011 Oct 25.[Epub ahead of print]Google Scholar
  24. 24.
    ICRP (1991) 1990 Recommendations of the International Commission on Radiological Protection. Ann ICRP 21(1–3):1–201Google Scholar
  25. 25.
    ICRP (2007) The 2007 Recommendations of the International Commission on Radiological Protection. ICRP Publication 103. Ann ICRP 37(2–4):1–332Google Scholar
  26. 26.
    ICRP (1991) Radiological Protection in Biomedical Research. A report of Committee 3 adopted by the International Commission on Radiological Protection. Ann ICRP 22(3):1–28, v–xxivCrossRefGoogle Scholar
  27. 27.
    “Radioactive drugs for certain research uses.” Code of Federal Regulations Title 21, Part 361.1 2011. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=361.1 Accessed 22 June 2011

Copyright information

© World Molecular Imaging Society 2011

Authors and Affiliations

  • Robert A. Comley
    • 1
  • Cristian Salinas
    • 1
  • Romina Mizrahi
    • 2
  • Irina Vitcu
    • 2
  • Alvina Ng
    • 2
  • William Hallett
    • 1
  • Nicholas Keat
    • 1
  • Alan A. Wilson
    • 2
  • Eugenii A. Rabiner
    • 1
  • Marc Laruelle
    • 1
  • Sylvain Houle
    • 2
  1. 1.GlaxoSmithKline Clinical Imaging CentreLondonUK
  2. 2.Centre for Addiction and Mental HealthTorontoCanada

Personalised recommendations